



UNITED STATES  
**NUCLEAR REGULATORY COMMISSION**  
REGION I  
475 ALLENDALE ROAD  
KING OF PRUSSIA, PENNSYLVANIA 19406-1415

June 24, 2005

Docket No. 03003294  
Control No. 136978

License No. 44-13760-01

Katherine Anderson  
Interim CEO  
Brattleboro Memorial Hospital  
17 Belmont Avenue  
Brattleboro, VT 05301

**SUBJECT: BRATTLEBORO MEMORIAL HOSPITAL, LICENSE AMENDMENT, CONTROL NO. 136978**

Dear Ms. Anderson:

This refers to your license amendment request dated April 22, 2005. Enclosed with this letter is the amended license deleting the requested authorized users and adding Michael Resnick, M.D., as an authorized user for 10 CFR 35.100 and 35.200 uses.

Please note the following:

- 1) 10 CFR 35.300 uses authorized in section 9.C. of your license have been modified to exclude the treatment of thyroid carcinoma. This action was necessary since there are no authorized users for thyroid carcinoma treatments listed on your license.
- 2) The following documents that were previously tied to your license under license condition 15 have been removed since issues described in these letters were either incorporated in your license or superceded by subsequent documents:
  - Letter dated January 30, 1992
  - Letter dated April 16, 1992
  - Letter dated July 1, 1993
  - Letter dated July 28, 1993
  - Letter dated September 29, 1993
  - Letter dated April 7, 1995
  - Letter dated January 23, 2001
  - Letter dated August 5, 2004
- 3) The former nuclear medicine hot lab and scan room described in attachment 9.1 of your application dated August 15, 1991, were released for unrestricted use pursuant to our letter dated May 16, 1995, upon review of your surveys submitted April 7, 1995.

Please review the enclosed document carefully and be sure that you understand and fully implement all the conditions incorporated into the amended license. Please note the last condition on your license indicates that, "This license condition applies only to those procedures that are required to be submitted in accordance with the regulations." Therefore, any procedure

K. Anderson  
Brattleboro Memorial Hospital

2

submitted that were not required by regulation to be submitted, e.g., procedures with Radiation Safety Committee meeting frequency requirements, will not be considered a part of your license and were not reviewed during the licensing process. If there are any errors or questions, please notify the U.S. Nuclear Regulatory Commission, Region I Office, Licensing Assistance Team, (610) 337-5239, so that we can provide appropriate corrections and answers.

An environmental assessment for this action is not required, since this action is categorically excluded under 10 CFR 51.22(c)(14).

Current NRC regulations and guidance are available at the NRC web site at <http://www.nrc.gov/materials/miau/mat-toolkits.html> and <http://www.nrc.gov/who-we-are/governing-laws.html> or by contacting the Government Printing Office (GPO) toll-free at 1-888-293-6498. The GPO is open from 7:00 a.m. to 9:00 p.m. EST, Monday through Friday (except Federal holidays).

Thank you for your cooperation.

Sincerely,

***Original signed by Penny Lanzisera***

Penny Lanzisera  
Senior Health Physicist  
Medical Branch  
Division of Nuclear Materials Safety

Enclosure:  
Amendment No. 36

cc:  
Peter D. Gibbons, M.D., Radiation Safety Officer

DOCUMENT NAME: G:\Docs\Mailed\Lic Cvr Letter\44-13760-01.136978.06262005.wpd

To receive a copy of this document, indicate in the box: "C" = Copy w/o attach/encl "E" = Copy w/ attach/encl "N" = No copy

OFFICE	DNMS/RI	N	DNMS/RI	N	DNMS/RI			
NAME	CHott/PAN for CAH7		PLanzisera/PAN					
DATE	6/24/2005		6/24/2005					

OFFICIAL RECORD COPY

**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Brattleboro Memorial Hospital</p> <p>2. 17 Belmont Avenue Brattleboro, Vermont 05301</p>	<p>In accordance with the letter dated April 22, 2005,</p> <p>3. License number 44-13760-01 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date September 30, 2012</p> <hr/> <p>5. Docket No. 030-03294 Reference No.</p>
--	--

<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Iodine 131 permitted by 10 CFR 35.300</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. 30 millicuries</p>
--	---	--

9. Authorized use:

A. Any uptake, dilution and excretion procedure permitted by 10 CFR 35.100.

B. Any imaging and localization procedure permitted by 10 CFR 35.200.

C. Any sodium iodide iodine-131 imaging and localization study or therapy procedure permitted by 10 CFR 35.300, except thyroid carcinoma, for which the patient can be released under the provisions of 10 CFR 35.75.

**CONDITIONS**

- 10. Licensed material may be used or stored only at the licensee's facilities located at 17 Belmont Avenue, Brattleboro, Vermont.
- 11. The Radiation Safety Officer for this license is Peter Gibbons, M.D.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
44-13760-01

Docket or Reference Number  
030-03294

Amendment No. 36

12. Licensed material is only authorized for use by, or under the supervision of:

- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for the materials and uses indicated:

Authorized Users

Material and Use

Peter Gibbons, M.D.

35.100; 35.200; oral administration of sodium iodide iodine-131 for imaging and localization studies and treatment of hyperthyroidism and cardiac dysfunction.

Laurie Cummings, M.D.


35.100; 35.200; iodine-131 sodium iodide for imaging and localization studies

Michael D. Resnik, M.D.

35.100; 35.200

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing financial assurance for decommissioning.


14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."



**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**License Number  
44-13760-01Docket or Reference Number  
030-03294

Amendment No. 36

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated August 15, 1991, except attachment 9.1
  - B. Letter dated March 9, 1992
  - C. Letter dated March 28, 1992
  - D. Letter dated March 22, 1994
  - E. Letter dated April 14, 1994
  - F. Letter dated February 8, 2002 (ML020500069)
  - G. Letter dated May 10, 2002 (ML021430123)



For the U.S. Nuclear Regulatory Commission

***Original signed by Penny Lanzisera***Date June 24, 2005

By \_\_\_\_\_

Penny Lanzisera  
Medical Branch  
Division of Nuclear Materials Safety  
Region I  
King of Prussia, Pennsylvania 19406